Approximately 70% of breast cancers are hormone receptor (HR)-positive (Normanno et al. 2005) and can potentially benefit from therapies targeted to the estrogen receptor, such as aromatase inhibit...
No takes yet. Share an insight, caveat, or question.
Kaklamani et al. (2009) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: